Estimation of CYP 2 D 6*10 genotypes on citalopram disposition in C hinese subjects by population pharmacokinetic assay
dc.contributor.author | Chen, B. | en_US |
dc.contributor.author | Xu, Y. | en_US |
dc.contributor.author | Jiang, T. | en_US |
dc.contributor.author | Feng, R. | en_US |
dc.contributor.author | Sun, J. | en_US |
dc.contributor.author | Zhang, W. | en_US |
dc.contributor.author | Yang, W. | en_US |
dc.contributor.author | Li, J. | en_US |
dc.contributor.author | Adeniyi, O. | en_US |
dc.contributor.author | Chen, H. | en_US |
dc.date.accessioned | 2013-11-01T19:00:47Z | |
dc.date.available | 2015-01-05T13:54:44Z | en_US |
dc.date.issued | 2013-12 | en_US |
dc.identifier.citation | Chen, B.; Xu, Y.; Jiang, T.; Feng, R.; Sun, J.; Zhang, W.; Yang, W.; Li, J.; Adeniyi, O.; Chen, H. (2013). "Estimation of CYP 2 D 6*10 genotypes on citalopram disposition in C hinese subjects by population pharmacokinetic assay." Journal of Clinical Pharmacy and Therapeutics 38(6): 504-511. | en_US |
dc.identifier.issn | 0269-4727 | en_US |
dc.identifier.issn | 1365-2710 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/100259 | |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Citalopram | en_US |
dc.subject.other | Genotype | en_US |
dc.subject.other | CYP 2 D 6 | en_US |
dc.subject.other | CYP 2 C 19 | en_US |
dc.subject.other | Population Pharmacokinetic | en_US |
dc.subject.other | Non‐Compartment | en_US |
dc.subject.other | Bioequivalence | en_US |
dc.title | Estimation of CYP 2 D 6*10 genotypes on citalopram disposition in C hinese subjects by population pharmacokinetic assay | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/100259/1/jcpt12029.pdf | |
dc.identifier.doi | 10.1111/jcpt.12029 | en_US |
dc.identifier.source | Journal of Clinical Pharmacy and Therapeutics | en_US |
dc.identifier.citedreference | Kobayashi K, Chiba K, Yagi T et al. Identification of cytochrome P450 isoforms involved in citalopram N‐demethylation by human liver microsomes. J Pharmacol Exp Ther, 1997; 280: 927 – 933. | en_US |
dc.identifier.citedreference | Rochat B, Amey M, Gillet M, Meyer UA, Baumann P. Identification of three cytochrome P450 isozymes involved in N‐demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics, 1997; 7: 1 – 10. | en_US |
dc.identifier.citedreference | de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S‐mephenytoin metabolism in humans. J Biol Chem, 1994; 269: 15419 – 15422. | en_US |
dc.identifier.citedreference | Olesen OV, Linnet K. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA‐expressed cytochrome P450 enzymes. Pharmacology, 1999; 59: 298 – 309. | en_US |
dc.identifier.citedreference | Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol, 1995; 10 ( Suppl 1 ): 15 – 21. | en_US |
dc.identifier.citedreference | Joffe P, Larsen FS, Pedersen V, Ring‐Larsen H, Aaes‐Jørgensen T, Sidhu J. Single‐dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol, 1998; 54: 237 – 242. | en_US |
dc.identifier.citedreference | Leinonen E, Lepola U, Koponen H, Kinnunen I. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit, 1996; 18: 111 – 117. | en_US |
dc.identifier.citedreference | Fredricson Overø K. Kinetics of citalopram in man: plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry, 1982; 6: 311 – 318. | en_US |
dc.identifier.citedreference | Sindrup SH, Brøsen K, Hansen MG, Aaes‐Jørgensen T, Overø KF, Gram LF. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit, 1993; 15: 11 – 17. | en_US |
dc.identifier.citedreference | Maier GA, Lockwood GF, Oppermann JA, Wei G, Bauer P, Fedler‐Kelly J, Grasela T. Characterization of the highly variable bioavailability of tiludronate in normal volunteers using population pharmacokinetic methodologies. Eur J Drug Metab Pharmacokinet, 1999; 24: 249 – 254. | en_US |
dc.identifier.citedreference | Fradette C, Lavigne J, Waters D, Ducharme MP. The utility of the population approach applied to bioequivalence in patients. Ther Drug Monit, 2005; 27: 592 – 600. | en_US |
dc.identifier.citedreference | Herrlin K, Yasui‐Furukori N, Tybring G, Widén J, Gustafsson LL, Bertilsson L. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol, 2003; 56: 415 – 421. | en_US |
dc.identifier.citedreference | Yu BN, Chen GL, He N, Ouyang DS, Chen XP, Liu ZQ, Zhou HH. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos, 2003; 31: 1255 – 1259. | en_US |
dc.identifier.citedreference | Spigset O, Hägg S, Stegmayr B, Dahlqvist R. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol, 2000; 56: 699 – 703. | en_US |
dc.identifier.citedreference | Friberg LE, Isbister GK, Hackett LP, Duffull SB. The population pharmacokinetics of citalopram after deliberate self‐poisoning: a Bayesian approach. J Pharmacokinet Pharmacodyn, 2005; 32: 571 – 605. | en_US |
dc.identifier.citedreference | Bies RR, Feng Y, Lotrich FE, Kirshner MA, Roose S, Kupfer DJ, Pollock BG. Utility of sparse concentration sampling for citalopram in elderly clinical trial subjects. J Clin Pharmacol, 2004; 44: 1352 – 1359. | en_US |
dc.identifier.citedreference | Kragh‐Sørensen P, Overø KF, Petersen OL, Jensen K, Parnas W. The kinetics of citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol (Copenh), 1981; 48: 53 – 60. | en_US |
dc.identifier.citedreference | Pentikis HS, Henderson JD, Tran NL, Ludden TM. Bioequivalence: individual and population compartmental modeling compared to the noncompartmental approach. Pharm Res, 1996; 13: 1116 – 1121. | en_US |
dc.identifier.citedreference | Jiang T, Rong Z, Peng L et al. Simultaneous determination of citalopram and its metabolite in human plasma by LC‐MS/MS applied to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci, 2010; 878: 615 – 619. | en_US |
dc.identifier.citedreference | Cai WM, Chen B, Zhang WX. Frequency of CYP2D6 *10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population. Clin Pharmacol Ther, 2007; 81: 95 – 98. | en_US |
dc.identifier.citedreference | Lee EJ, Jeyaseelan K. Frequency of human CYP2D6 mutant alleles in a normal Chinese population. Br J Clin Pharmacol, 1994; 37: 605 – 607. | en_US |
dc.identifier.citedreference | Garcia‐Barcelo M, Chow LY, Chiu HF, Wing YK, Lee DT, Lam KL, Waye MM. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin Chem, 2000; 46: 18 – 23. | en_US |
dc.identifier.citedreference | Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, Huang JD. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos, 2001; 29: 268 – 273. | en_US |
dc.identifier.citedreference | Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. Biochem Pharmacol, 1992; 43: 2201 – 2208. | en_US |
dc.identifier.citedreference | Yin OQ, Wing YK, Cheung Y, Wang ZJ, Lam SL, Chiu HF, Chow MS. Phenotype‐genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol, 2006; 26: 367 – 372. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.